Results 21 to 30 of about 2,313 (149)
Biomedicines, 2023 Monoclonal antibody-based therapy has shown efficacy against cancer, autoimmune, infectious, and inflammatory diseases. Multispecific antibodies (MsAbs), including trispecifics (tsAbs), offer enhanced therapeutic potential by targeting different epitopes.
Maria João Sebastião +7 more
doaj +1 more source
Emerging new therapeutic antibody derivatives for cancer treatment
Signal Transduction and Targeted Therapy, 2022 Monoclonal antibodies constitute a promising class of targeted anticancer agents that enhance natural immune system functions to suppress cancer cell activity and eliminate cancer cells.
Shijie Jin +7 more
doaj +1 more source
Computational and Structural Biotechnology Journal, 2020 Multispecific antibodies can be generated in different formats. More than two decades of R&D in the field of bispecific antibody engineering revealed that the design and choice of format can have a profound impact on the antibody functionality.
Steffen Dickopf +2 more
doaj +1 more source
mAbs, 2021 Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka +2 more
doaj +1 more source
VERITAS: Harnessing the power of nomenclature in biologic discovery
mAbs, 2023 We are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision.
Riti Biswas +6 more
doaj +1 more source
Scientific Reports, 2023 The landscape of current cancer immunotherapy is dominated by antibodies targeting PD-1/PD-L1 and CTLA-4 that have transformed cancer therapy, yet their efficacy is limited by primary and acquired resistance. The blockade of additional immune checkpoints,
Riyao Yang +14 more
doaj +1 more source
Engineering multi-specific antibodies against HIV-1
Retrovirology, 2018 As increasing numbers of broadly neutralizing monoclonal antibodies (mAbs) against HIV-1 enter clinical trials, it is becoming evident that combinations of mAbs are necessary to block infection by the diverse array of globally circulating HIV-1 strains ...
Neal N. Padte +3 more
doaj +1 more source
Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
Frontiers in Immunology, 2023 To construct a trispecific IgG-like antibody at least three different binding moieties need to be combined, which results in a complex architecture and challenging production of these molecules.
Julia Harwardt +9 more
doaj +1 more source
Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
mAbs, 2023 Upon reformatting of an antibody to single-chain variable fragment format, a region in the former variable/constant domain interface of the heavy chain becomes accessible for preexisting (PE) anti-drug antibody (ADA) binding.
Maria U. Johansson +12 more
doaj +1 more source
Engineering a pure and stable heterodimeric IgA for the development of multispecific therapeutics
mAbs, 2022 Immunoglobulin G (IgG) has served as a traditional framework for antibody-based biology, and engineering approaches for creating multispecific therapeutics have greatly expanded its applicability.
Florian Heinkel +11 more
doaj +1 more source